The world’s first COVID-19 human challenge is about to start.
Britain will infect 2,500 healthy volunteers with coronavirus to study how the infection behaves in the body — specifically the amount it takes before a person develops Covid-19, the Sun reported.
The government has budgeted $45 million for the research, which is being conducted by Imperial College, the National Health Service’s Royal Free Hospital and pharmaceutical company hVIVO, a pioneer in viral human challenge models.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).